Mandate

Vinge advised Lifco on IPO

November 21, 2014

The class B shares of Lifco AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm, following an offering to the general public in Sweden and to institutional investors in Sweden and abroad. The price in the offering was SEK 93 per share, corresponding to a market value of all Lifco shares of approximately SEK 8.4 billion.

Vinge advised Lifco. The Vinge team primarily consisted of Erik Gabrielson, Erik Sjöman, Jesper Schönbeck, Anna Edström and Christian Lindhé, together with a large number of other associates and specialist partners.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025